Comparison of pulmonary function changes between patients receiving neoadjuvant chemotherapy and chemoradiotherapy prior to minimally invasive esophagectomy: a randomized and controlled trial

Xiaosang Chen1 · Mingjun Du2 · Han Tang1 · Hao Wang1 · Yong Fang1 · Miao Lin1 · Jun Yin1 · Lijie Tan1 · Yaxing Shen1,2

Received: 30 November 2021 / Accepted: 1 August 2022 / Published online: 25 August 2022 © The Author(s) 2022

Abstract
Purpose Adequate pulmonary function is important for patients undergoing surgical resection of esophageal cancer, especially those that received neoadjuvant therapy. However, it is unknown if pre-operative radiation affects pulmonary function differently compared to chemotherapy. The purpose of this study was to compare changes in pulmonary function between patients undergoing minimally invasive esophagectomy (MIE) who received neoadjuvant chemotherapy or chemoradiotherapy.

Methods Between March 2017 and March 2018, esophageal cancer patients requiring neoadjuvant therapy were prospectively enrolled and randomly assigned to receive chemotherapy (CT) or chemoradiotherapy (CRT) before MIE. All patients received pulmonary function testing before and after the neoadjuvant therapy. Changes in pulmonary function, operative data, and pulmonary complications were compared between the 2 groups.

Results A total of 71 patients were randomized and underwent MIE after receiving CT (n = 34) or CRT (n = 37). Baseline clinical characteristics were comparable between the 2 groups. The CRT group experienced a greater decrease of forced expiratory volume at 1 s (FEV1) (2.66 to 2.18 L, p = 0.023) and diffusion capacity of the lung for carbon monoxide divided by the mean alveolar volume (DLCO/Va) (17.3%, p < 0.001) than the CT group (FEV1 2.53 to 2.41 L; DLCO/Va 4.8%). The incidence of pulmonary complications was higher in the CRT group (13.51 vs. 8.82%), but the difference was not significant (p = 0.532).

Conclusions Preoperative CRT affects pulmonary function more than CT alone, but does not increase the risk of pulmonary complications in patients undergoing MIE.

Keywords Esophageal cancer · Neo-adjuvant therapy · Pulmonary function

Introduction

Neoadjuvant therapy is indicated in the treatment of locally advanced esophageal cancer due to both surgical and oncological benefits [1–5]. However, neoadjuvant therapy can increase the risk of pulmonary complications, and thus perioperative morbidity and mortality [6, 7]. As such, adequate pulmonary function is important for achieving good outcomes in patients undergoing surgical resection of esophageal cancer.

Studies have provided interesting results with respect to the relation between pulmonary function and postoperative morbidity. Cerfolio et al. [8] described a decrease of...
pulmonary function after neoadjuvant therapy, which predicted increased postoperative morbidity in patients with non-small cell lung cancer (NSCLC) undergoing surgery. Abou-Jawde et al. [9] reported that neoadjuvant therapy was associated with decreased pulmonary function and increased acute respiratory complications in patients with esophageal cancer undergoing surgery. However, their results were from a retrospective analysis of 3 clinical trials with high heterogeneity. Currently, it is not known if neoadjuvant radiotherapy affects pulmonary function differently than chemotherapy alone, and if the changes in pulmonary function result in a different rate of surgical pulmonary complications.

Based on our previous experience performing minimally invasive esophagectomy (MIE) [10, 11], the purpose of this study was to compare changes in pulmonary function between patients undergoing MIE who received neoadjuvant chemotherapy or chemoradiotherapy, and determine if there were differences in outcomes and complications between the 2 groups.

**Patients and methods**

**Patients**

This study was a prospective, randomized, and controlled trial, and was registered at ClinicalTrials.gov (NCT03001596) [12]. It was approved by the Ethics Committee of Zhongshan Hospital, Fudan University, China (B2016-177R). Consecutive patients with locally advanced esophageal cancer, pursuant a standard staging procedure (endoscopy, tissue biopsy, computed tomography [CT], and positron emission tomography [PET]), and a histologically proven diagnosis of locally advanced esophageal cancer (cT3-4aN0-1M0) were enrolled. Complete inclusion and exclusion criteria are summarized in Supplementary Table 1.

Patients were randomized to receive neoadjuvant chemotherapy (CT) or neoadjuvant chemoradiotherapy (CRT) using a computer-generated list. Patients were randomly assigned to either group using sequentially numbered sealed envelopes containing information that disclosed the type of treatment.

**Neoadjuvant therapy protocols**

**Neoadjuvant CT**

Neoadjuvant CT consisted of 2 cycles of paclitaxel 175 mg/m² on day 1 and cisplatin 75 mg/m² on day 1/2 by intravenous infusion, with 3 weeks between cycles.

**Neoadjuvant CRT**

Neoadjuvant CRT consisted of concurrent preoperative radiotherapy and chemotherapy.

Radiation was administered based on the volume and location of the tumor. CT-based planning was performed for each patient. The total dose was 40 Gy, given in daily single 2 Gy fractions on days 1–5, 8–12, 15–19, and 22–26. Chemotherapy consisting of paclitaxel 50 mg/m² and cisplatin 25 mg/m² was administered on day 6, 13, 20, and 27.

**Surgery following neoadjuvant therapy**

MIE was performed 4–8 weeks after completion of neoadjuvant therapy. MIE consisted of 3 stages (thoracic, abdominal, and cervical stages), and the details of the surgery have been previously published [10, 11]. The thoracic stage included esophageal mobilization and mediastinal lymphadenectomy. Patients were placed in a semi-prone position with the right arm raised above the head and the right side of the operating table slightly raised. The surgeon stood on the right side of the patient. An observation port was placed at the seventh intercostal space (ICS) along the mid-axillary line, and another 10-mm port was placed at the ninth ICS along the scapular line. Two 5-mm ports were placed at the third ICS along the mid-axillary line, and just inferior to the tip of the scapula, respectively. An artificial CO₂ pneumothorax was achieved at a pressure of 8 mm Hg. After thoracoscopic exploration, the azygous vein was double-ligated by Hem-o-locks and then divided, followed by mobilization of the thoracic esophagus. The thoracic duct was identified and carefully preserved. The esophageal arteries were divided with a harmonic scalpel, and mediastinal lymph nodes, including lymph nodes along the bilateral recurrent laryngeal nerves and subcarinal lymph node, were removed en bloc. The thoracic procedure was completed by placement of intercostal drains and closure of the thoracic ports. The abdominal and cervical stages were the same as described previously [13–16]. The operation concluded with closure of the cervical and abdominal incisions in layers.

**Pulmonary function testing**

Pulmonary function tests (PFTs) were performed before and 6 weeks after neoadjuvant therapy, using the Spirometer System (Biomedin, Padua, Italy). PFT parameters collected included vital capacity (VC), forced vital capacity (FVC), forced expiratory volume at 1 s (FEV₁), total lung capacity (TLC), residual volume (RV), peak expiratory flow (PEF), diffusion capacity of the lung for carbon monoxide by single breath method (DLCO/SB), and the DLCO divided by the mean alveolar volume (DLCO/Va). Blood atrial gas analysis was performed by sampling of the radial artery blood.
Pulmonary complications

Postoperative complications were defined by reference to the Society of Thoracic Surgeons (STS) database, and definitions from the official website of the International Society for the Diseases of Esophagus (ISDE). Chest radiographs were obtained to evaluate for possible pulmonary complications when necessary. Pulmonary complications were defined as the primary morbidity in the following situations: (1) a therapeutic bronchoscopy/tracheotomy was performed due to bronchial secretions; (2) pneumonia was diagnosed per clinical and radiographic criteria; (3) the occurrence of acute lung injury/acute respiratory distress syndrome (ARDS); (4) the development of a pleural effusion requiring an additional drainage procedure; (5) mucous plugging requiring bronchoscopy; and (6) occurrence of a pulmonary embolism. Mortality was defined as death before discharge or within 30 days of the operation.

Statistical analysis

Clinical data for all enrolled patients were collected from the clinical database of our institution. All data were tabulated using Microsoft Excel (Microsoft, Redmond, WA), and statistical analysis was performed with SPSS version 17.0 software (SPSS, Inc., Chicago, IL). Variables were compared using the Mann–Whitney test, the Student t test, the Chi-square test, and Fisher’s exact test, as appropriate. A 2-tailed value of \( p < 0.05 \) was considered statistically significant.

Results

Patient demographic characteristics

Recruitment occurred from March 2017 to March 2018, and a total of 76 patients met the inclusion criteria and were deemed eligible for the study. One patient of the 76 declined to participate in the study and the remaining 75 patients were randomized to the CT group or CRT group. Subsequently, 4 patients discontinued the study (2 with disease progression and 2 who subsequently refused surgery). Thus, 71 patients were included in the analysis and underwent MIE after receiving CT (\( n = 34 \)) or CRT (\( n = 37 \)).

A flow diagram of patient inclusion is shown in Fig. 1, and patient demographic and clinical features are summarized in Table 1. Specifically, no patients with asthma, chronic obstructive pulmonary disease, or interstitial lung disease were enrolled. No esophageal tumor initially invaded or made an impression of the trachea were found from CT-scan in this study.

Changes in pulmonary function

All patients received PFTs before and 6 weeks after the neoadjuvant therapy during pre-operation assessment, and no patients were excluded from the surgery due to decreased pulmonary function. In the CRT group, the average \( \text{FEV}_1 \) decreased from 2.66 to 2.18 L, while in the CT group the average \( \text{FEV}_1 \) decreased from 2.53 to 2.41 L. The decrease of \( \text{FEV}_1 \) in the CRT group reached statistical difference (\( p=0.023 \)), while the decrease in the CT group did not.

Fig. 1 Flow diagram of patient inclusion. CT, chemotherapy; CRT, chemoradiotherapy
DLCO/Va decreased by 17.3% in the CRT group and 4.8% in CT group \( (p < 0.001) \). A summary of PFTs results is shown in Fig. 2.

### Pulmonary complications

A total of 8 patients (11.27%) developed pulmonary complications: 5 patients (13.51%) in CRT group and 3 patients (8.82%) in CT group. The frequency of pulmonary complications between the 2 groups was not statistically different \( (p = 0.532) \). Pulmonary complications included 2 cases of ARDS, 2 cases of pneumonia, 3 cases of pleural effusion requiring chest tube insertion and drainage, and 1 case of atelectasis. All complications resolved with appropriate management. In the 2 cases of ARDS, patients were provided nasal/mask oxygen inhalation. The other 6 patients

| Table 1 Patient demographic and clinical characteristics | CT \( (n = 34) \) | CRT \( (n = 37) \) | \( p \) value |
|-------------|-------------|-------------|----------------|
| Age (years) | 62.7 ± 6.5  | 64.3 ± 7.1  | 0.779*         |
| Sex (M:F)   | 26:8        | 29:8        | 0.848†         |
| Location (U:M:L) | 5:25:4       | 6:23:8       | 0.974‡         |
| cStage (T3:T4) | 27:7        | 32:5        | 0.427‡         |
| Ex-smokers  | 14          | 15          | 0.957†         |
| ASA (I:II)  | 12:22       | 14:23       | 0.824†         |

Data are presented as mean ± standard deviation, or number
CT, chemotherapy; CRT, chemo-radiation therapy; ASA, American Society of Anesthesiologists

*Student t test
†Chi-square test
‡Fisher exact test

**Fig. 2** Changes in pulmonary function before and after neoadjuvant therapy. CT: \( \text{FEV}_1 \) decrease from 2.53 to 2.41 L. CRT: \( \text{FEV}_1 \) decrease from 2.66 to 2.18 L. CT: Average DLCO/Va decrease 4.8%. CRT: Average DLCO/Va decrease 17.3%. The CRT group experienced a greater decrease in both \( \text{FEV}_1 \) \( (p = 0.023) \) and DLCO/Va \( (p < 0.001) \) than the CT group. CT, chemotherapy; CRT, chemoradiotherapy
were provided nasal oxygen inhalation intermittently when they felt dyspnea. A summary of pulmonary complications is shown in Fig. 3.

**Discussion**

The results of this study showed that patients who received CRT had a greater decrease in FEV₁ and DLCO/Va than patients that received CT; however, the frequency of pulmonary complications was not different between the 2 groups. How far these PFT parameters decline correlates with clinical worsening of the patients, and remains unclear at this current study. Minimally clinical important difference (MCID) is a useful expression defined as the minimal amount of change required to be confident that a patient has truly changed. Considering the fact that there has been little evidence on MCID for FEV₁ and DLCO in patients underwent neoadjuvant therapy and the relatively small sample size of this study, MCID has not been evaluated in this study. MCID would be estimated in further work with a bigger sample size to determine if changes of PFTs are clinically important for the patient.

Published evidence has shown that CRT or CT provides a survival benefit over surgery alone for locally advanced esophageal cancer [5, 6]. However, neoadjuvant therapy potentially increases the risk of postoperative morbidity and mortality and thus imposes restrictions on the application of neoadjuvant therapy, especially CRT. Recently, Yong et al. [17] conducted a randomized trial comparing the outcomes of CRT followed by surgery with surgery alone in esophageal cancer patients. The study showed that 17% of patients in the CRT group did not undergo surgery after CRT, and 54.3% of CRT patients developed grade 3 or 4 hematologic toxicity, suggesting that neoadjuvant therapy increased perioperative risks. MIE is associated with less trauma than open surgery and a similar curative effect, and MIE has been shown to be associated with improved perioperative outcomes, including a decrease of pulmonary complications [18, 19]. However, respiratory morbidity is still the most frequent complication after esophagectomy despite the development of advanced surgical and perioperative management techniques.

Many studies have demonstrated the detrimental effects of neoadjuvant therapy on pulmonary function [20, 21]. A correlation between PFTs changes after induction therapy and respiratory morbidity has been reported in patients with non-small cell lung cancer (NSCLC). Cerfolio et al. [8] reported that a decrease of DLCO/Va after neoadjuvant therapy may predict increased postoperative morbidity, especially if the decrease is 8% or greater. Margaritora et al. [22] reported a 22.8% decrease of DLCO in patients after induction chemoradiotherapy, but they did not compare the relations between the change of PFTs and incidence of postoperative complications. Despite increasing application of neoadjuvant therapy, its impact on pulmonary function and pulmonary complications has not been fully investigated in the setting of esophageal cancer surgery. Abou-Jawde et al. [9] reported that CRT was associated with significant decreased DLCO in patients with esophageal cancer, and the decrease was greater in patients that received 45 Gy than those that received 30 Gy. Post-CRT DLCO was also worse in patients with postoperative acute respiratory complications. However, the study was a retrospective analysis of 3 clinical trials, and some of PFT data, particularly pretreatment DLCO values, were missing. Considering the retrospective nature and heterogeneity of previous studies, we conducted this prospective, randomized, controlled trial to

![Fig. 3 Pulmonary complications after minimally invasive esophagectomy. A total of 8 patients (11.27%) developed pulmonary complications: 5 patients (13.51%) in CRT group and 3 patients (8.82%) in CT group. The frequency of pulmonary complications between the 2 groups was not statistically different (p=0.532). Pulmonary complications included 2 cases of ARDS, 2 cases of pneumonia, 3 cases of pleural effusion requiring chest tube insertion and drainage, and 1 case of atelectasis. All complications resolved with appropriate management.](image-url)
evaluate the relations between PFT changes and postoperative pulmonary complications in patients undergoing MIE, and to determine if there were differences between patients that received neoadjuvant CT or CRT.

A prior study reported that changes in pulmonary function were an independent risk factor for primary pulmonary complications in patients undergoing surgery for esophageal cancer [23]. Pulmonary complications were defined as a primary postoperative morbidity in this study because secondary pulmonary complications are more serious conditions, such as aspiration and leakage after surgery [24]. Since lymphadenectomy along the bilateral recurrent laryngeal nerves is conventionally performed during esophagectomy, patients are at high risk of vocal cord palsy and aspiration pneumonia. In addition, nasogastric tubes are commonly used for gastric conduit decompression after esophagectomy, which can cause discomfort and inhibit expectoration, and thus increase the risk of aspiration [25]. Anastomotic leakage, which occurs with relatively high frequency after esophagectomy, can lead to severe infection in the thoracic cavity. Additionally, a patient’s nutritional and immune state can be severely affected, causing rapid deterioration of their general condition which predisposes to serious infection. Compared to chemotherapy alone, neoadjuvant radiation increases tissue edema, inflammation, and fibrosis, with a subsequent higher risk of perioperative morbidity. Hence, secondary pulmonary complications tend to be the consequence of complicated surgical procedure and other postoperative morbidities, rather than a patient’s respiratory reserve, and thus were excluded from the evaluation in this study.

It has been reported that spirometry can help predict the likelihood of pulmonary complications. Generally, FEV₁ reflects pulmonary ventilation function, and DLCO represents functional gas exchange capacity [26]. Takeda et al. [27] and Leo et al. [6] reported lower DLCO/Va and higher FEV₁ after induction therapy in patients with NSCLC. Multivariate analysis revealed that DLCO was an independent factor predictive of pulmonary morbidity. Improved FEV₁ after neoadjuvant therapy may result from relief in bronchial obstruction caused by tumor extension or enlarged lymph nodes. Unlike patients with NSCLC whose volume of lung may improve, patients with esophageal cancer tend to have unchanged or worse FEV₁ after neoadjuvant therapy. Ferguson et al. [23] reported FEV₁ can help predict the likelihood of pulmonary complications after esophagectomy. Radiation and chemotherapy can worsen gas exchange, and it has been proposed that DLCO assessed after neoadjuvant therapy was superior to FEV₁ as a predictor of pulmonary complications [22].

Some chemotherapeutic agents, such as cisplatin, can cause a decline in alveolo-capillary membrane diffusion capacity by a mechanism that resembles the pathogenesis of ARDS [28, 29], and the addition of radiation to chemotherapy can enhance pulmonary toxicity. Since the degree of subclinical damage to the alveolo-capillary membrane is proportional to DLCO/Va decrease, the measurement of DLCO/Va may be more sensitive for predicting pulmonary complications.

No patients died in our study. Though patients in the CRT group had a greater decrease of FEV₁ and DLCO/Va than patients in the CT group, the frequency of pulmonary complications was similar between the 2 groups. It is possible that the lack of difference in the pulmonary complication rate was due to the relatively small sample size. However, our results do provide proof that CRT depresses pulmonary function more than CT alone. Possible explanations include that radiation-induced pulmonary fibrosis and lymphocytopenia may occur as a result of radiation, resulting in interstitial infiltrates. In this study, 2 cases of ARDS and 2 cases of pneumonia (3 patients in CRT group and 1 patient in CT group) were found in CT-scan, which could be the result of interstitial infiltrates. A higher rate of interstitial infiltrates in CT-scan was found in CRT group, correlated to the decline of FEV₁ and DLCO. The correlation between pulmonary complications and decline of PFT parameters remains unclear, which should be explored in some pulmonary function rehabilitation study following this observational research. One important clinical finding of this study is that if DLCO/Va and FEV₁ decrease significantly after neoadjuvant therapy, the risk of pulmonary complications can be increased. Our results suggest that evaluation of PFTs may help identify patients at increased risk of pulmonary complications and thus permit appropriate interventions to decrease the risk and improve outcomes.

The limitations of this study are that it was performed at a single institution, and the number of enrolled patients was limited. The strengths of this study include the well-defined inclusion criteria and the homogeneous patient population.

**Conclusions**

For esophageal cancer patients undergoing neoadjuvant therapy, CRT affects pulmonary function more than CT alone, and may increase the risk of pulmonary complications. A decline of FEV₁ and DLCO/Va after neoadjuvant therapy should be considered in the preoperative risk assessment of patients undergoing MIE.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00423-022-02646-x.

**Funding** Supported by Program of The Science and Technology Commission of Shanghai Municipality (22Y11907200).
Declarations

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijhoven BP et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074–2084. https://doi.org/10.1056/NEJMoa1112088
2. Pennathur A, Gibson MK, Jobe BA, Luketich JD (2013) Oesophageal carcinoma. Lancet 381(9864):400–412. https://doi.org/10.1016/s0140-6736(12)60643-6
3. Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijhoven BPL et al (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16(9):1090–1098. https://doi.org/10.1016/s1470-2045(15)00040-6
4. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G et al (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29(15):1715–1721. https://doi.org/10.1200/jco.2010.33.0597
5. Jang R, Darling G, Wong RK (2015) Multimodality approaches for the curative treatment of esophageal cancer. J Natl Compr Canc Netw 13(2):229–238. https://doi.org/10.6004/jnccn.2015.0029
6. Leo F, Solli P, Spaggiari L, Veronesi G, de Braud F, Leon ME et al (2004) Respiratory function changes after chemotherapy: an additional risk for postoperative respiratory complications? Ann Thorac Surg 77(1):260–5. https://doi.org/10.1016/s0003-4975(03)01487-5 (discussion 5)
7. Mariette C, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B et al (2014) Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol 32(23):2416–2422. https://doi.org/10.1200/jco.2013.53.6532
8. Cerfolio RJ, Talat A, Bryant AS (2009) Changes in pulmonary function tests after neoadjuvant therapy predict postoperative complications. Ann Thorac Surg 88(3):930–5. https://doi.org/10.1016/j.athoracsur.2009.06.013 (discussion 5-6)
9. Abou-Jawde RM, Mkhaiti T, Adelstein DJ, Rybicki LA, Mazzone PJ, Caroli MA et al (2005) Impact of induction concurrent chemoradiotherapy on pulmonary function and postoperative acute respiratory complications in esophageal cancer. Chest 128(1):250–255. https://doi.org/10.1378/chest.128.1.250
10. Wang H, Shen Y, Feng M, Zhang Y, Jiang W, Xu S et al (2015) Outcomes, quality of life, and survival after esophagectomy for squamous cell carcinoma: a propensity score-matched comparison of operative approaches. J Thorac Cardiovasc Surg 149(4):1006–14. https://doi.org/10.1016/j.jtcvs.2014.12.063 (discussion 14-5, e4)
11. Shen Y, Zhong M, Wu W, Wang H, Feng M, Tan L et al (2013) The impact of tidal volume on pulmonary complications following minimally invasive esophagectomy: a randomized and controlled study. J Thorac Cardiovasc Surg 146(5):1267–73. https://doi.org/10.1016/j.jtcvs.2013.06.043 (discussion 73–4)
12. Tang H, Tan L, Shen Y, Wang H, Lin M, Feng M et al (2017) CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT(3–4a)N(0–1)M(0)) (NCT03001596). BMC Cancer 17(1):450. https://doi.org/10.1186/s12885-017-3446-7
13. Luketich JD, Alvelo-Rivera M, Buenaventura PO, Christie NA, McCaughan JS, Little VR et al (2003) Minimally invasive esophagectomy: outcomes in 222 patients. Ann Surg 238(4):486–94. https://doi.org/10.1097/01.sla.00000989858.40725.68 (discussion 94-5)
14. Palanivelu C, Prakash A, Senthilkumar R, Senthilnathan P, Parthasarathi R, Rajan PS et al (2006) Minimally invasive esophagectomy: thorascopic mobilization of the esophagus and mediastinal lymphadenectomy in prone position—experience of 130 patients. J Am Coll Surg 203(1):7–16. https://doi.org/10.1016/j.jamcollsurg.2006.03.016
15. Feng M, Shen Y, Wang H, Tan L, Zhang Y, Khan MA et al (2012) Thoracolaparoscopic esophagectomy: is the prone position a safe alternative to the decubitus position? J Am Coll Surg 214(5):838–844. https://doi.org/10.1016/j.jamcollsurg.2011.12.047
16. Shen Y, Zhang Y, Tan L, Feng M, Wang H, Khan MA et al (2012) Extensive mediastinal lymphadenectomy during minimally invasive esophagectomy: optimal results from a single center. J Gastrointest Surg 16(4):715–721. https://doi.org/10.1007/s11605-012-1824-7
17. Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z et al (2018) Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol 36(27):2796–2803. https://doi.org/10.1200/jco.2018.79.1483
18. Sihag S, Wright CD, Wain JC, Gaisser TA, Lanuti M, Allan JS et al (2012) Comparison of perioperative outcomes following open versus minimally invasive Ivor Lewis oesophagectomy at a single, high-volume centre. Eur J Cardiothorac Surg 42(3):430–437. https://doi.org/10.1093/ejcts/ezs031
19. Biere SS, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, Garcia JR et al (2012) Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 379(9829):1887–1892. https://doi.org/10.1016/s0140-6736(12)60516-9
20. Daddi R, Thomas P, Thirion X, Serée Y, Giudicelli R, Fuentes P (2001) Postoperative complications in relation with induction therapy for lung cancer. Eur J Cardiothorac Surg 20(2):385–390. https://doi.org/10.1016/s1010-7940(01)00764-3
21. Dimopoulos I, Galani H, Dafni U, Samakovli A, Roussos C, Dimopoulos MA (2002) A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin. Cancer 94(2):452–458. https://doi.org/10.1002/cncr.10182
22. Margaritora S, Cesario A, Cusumano G, Cafarotti S, Corbo GM, Ferri L et al (2010) Is pulmonary function damaged by neoadjuvant lung cancer therapy? A comprehensive serial time-trend analysis of pulmonary function after induction radiochemotherapy plus surgery. J Thorac Cardiovasc Surg 139(6):1457–1463. https://doi.org/10.1016/j.jtcvs.2009.10.023

23. Ferguson MK, Durkin AE (2002) Preoperative prediction of the risk of pulmonary complications after esophagectomy for cancer. J Thorac Cardiovasc Surg 123(4):661–669. https://doi.org/10.1067/mtc.2002.120350

24. Fang W, Kato H, Tachimori Y, Igaki H, Sato H, Daiko H (2003) Analysis of pulmonary complications after three-field lymph node dissection for esophageal cancer. Ann Thorac Surg 76(3):903–908. https://doi.org/10.1016/s0003-4975(03)00549-6

25. Sato T, Takayama T, So K, Murayama I (2007) Is retention of a nasogastric tube after esophagectomy a risk factor for postoperative respiratory tract infection? J Infect Chemother 13(2):109–113. https://doi.org/10.1007/s10156-007-0504-0

26. Hsia CC (2002) Recruitment of lung diffusing capacity: update of concept and application. Chest 122(5):1774–1783. https://doi.org/10.1378/chest.122.5.1774

27. Takeda S, Funakoshi Y, Kadota Y, Koma M, Maeda H, Kawamura S et al (2006) Fall in diffusing capacity associated with induction therapy for lung cancer: a predictor of postoperative complication? Ann Thorac Surg 82(1):232–236. https://doi.org/10.1016/j.athoracsur.2006.01.045

28. Pinson P, Klastersky J (1998) The value of lung function measurements for the assessment of chemotherapy in lung cancer patients. Lung Cancer 19(3):179–184. https://doi.org/10.1016/s0169-5002(97)00094-9

29. Maas KW, van der Lee I, Bolt K, Zanen P, Lammers JW, Schramel FM (2003) Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine/cisplatin as part of combined modality treatment. Lung Cancer 41(3):345–351. https://doi.org/10.1016/s0169-5002(03)00237-x

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.